Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 12, 2022 6:39pm
I want management to take some PR courses
and professional speaking seminars
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 12, 2022 3:11pm
Ate is in the wrong line of business
Alex Jones Still Sells Supplements On Amazon Despite Bans From Other Platforms Facebook Twitter Flipboard Email March 24, 20214:57 PM ET
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 12, 2022 3:07pm
Maybe
they can whip up a batch of anti-cancer elixir. they need to bring in some cash in case otena fails. lol. it worked for alex jones, he was selling 100's of thousands every month on supplements to
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 12, 2022 2:49pm
This is where the real money is
to bad these guys no zip about cancer) In nod to JFK, Biden returns to Boston to relaunch cancer moonshot initiative By Alexander Thompson Globe Correspondent,Updated September 11
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Sep 12, 2022 11:18am
PainWEEK poster ...
going up on ATE website today.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 12, 2022 10:24am
RE:RE:RE:Pezgoof, I have never made fun of stuttering.
It is funny to see that Stockings/Stutters have no interest in the company but continue to attack for their own pleasure. He still shows no focus on the business, no interest in the shares
...more
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Sep 12, 2022 8:58am
RE:RE:Pezgoof, I have never made fun of stuttering.
I guess this wouldn't be the first time someone spoke to themselves using 2 different forums. Reminds me of the dumpster messaging Czechcashings and then lying about it. deja vu LOL! get
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 11, 2022 11:55am
RE:RE:AGM ...
What I'm betting on has nothing to do with stock price movement- if/when the price moves, I'm ready. Do I think there's more value than the price is indicating? Sure do ! Do I think
...more
(2)
•••
Doccole
X
View Profile
View Bullboard History
Comment by
Doccole
on Sep 10, 2022 8:48pm
RE:AGM ...
Hopefully Dano can keep the crew on schedule. we only go up from here? Right? say they release the biz study.....is that going to increase the need to purchase the stock? I can't
...more
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Sep 10, 2022 8:29pm
RE:Pezgoof, I have never made fun of stuttering.
like putting pez as a teacher in anger management classes. Or pez as a kindergarten teacher when he is a smart as a kindergarten student
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Sep 10, 2022 6:56pm
Pezgoof, I have never made fun of stuttering.
I do however think that he should let someone else speak for the company as he is (in my opinion) a horrible public speaker and this in turn effects the share price and chance of any future success.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Sep 10, 2022 9:07am
AGM ...
15% of the shares voted - tells me mostly insiders with 1M-2M outside shares voted. (max). Roughly 8M of the 52M outstanding shares voted. --------------- CITA could close soon. Commercial study
...more
(450)
•••
davgro
X
View Profile
View Bullboard History
Comment by
davgro
on Sep 09, 2022 11:04pm
RE:RE:Alternative Trading Systems (ATS)
Total volume for ATE today was 31,967 shares, not the 11,200 stated by Stockhouse. T:ATE - ANTIBE THERAPEUTICS INC. J - https://www.antibethera.com 23:02:04 EDT
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 09, 2022 9:38pm
RE:Alternative Trading Systems (ATS)
what was total volume today then if trades register on the ATS, according to stockhouse it was 11,200 obviously not cause that's what it was before i bought shares.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 09, 2022 5:01pm
New Press Release - Antibe Announces Results of 2022 Annual Meeting
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today...
read article.
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >